Invention Grant
- Patent Title: Cancer-specific T-cell receptors
-
Application No.: US17119899Application Date: 2020-12-11
-
Publication No.: US12053513B2Publication Date: 2024-08-06
- Inventor: Andrew Sewell , Garry Dolton
- Applicant: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD.
- Applicant Address: GB Cardiff South Wales
- Assignee: University College Cardiff Consultants Ltd.
- Current Assignee: University College Cardiff Consultants Ltd.
- Current Assignee Address: GB Cardiff South Wales
- Agency: Dechert LLP
- Agent Andrew T. Wilkins
- Priority: GB 10358 2018.06.25
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K38/08 ; A61K39/00 ; A61P35/00 ; C07K7/06
Abstract:
The present disclosure relates to a new anti-cancer peptide; a vector encoding same; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said anti-cancer peptide; use of said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine to treat cancer; a method of treating cancer using said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine; and a combination therapeutic for the treatment of cancer comprising said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine.
Public/Granted literature
- US20210196807A1 CANCER-SPECIFIC T-CELL RECEPTORS Public/Granted day:2021-07-01
Information query
IPC分类:
